Quinine News and Research

RSS

FDA accepts Merck's JANUMET extended-release formulation NDA for type 2 diabetes

Merck today announced that the New Drug Application (NDA) for the Company's investigational extended-release formulation of JANUMET for type 2 diabetes has been accepted for standard review by the U.S. Food and Drug Administration (FDA). The Company is also moving forward as planned with regulatory filings in countries outside the United States.

12 Jan 2011

Malaria drug artesunate found more effective than quinine at preventing severe falciparum malaria deaths in children, study says

Researchers found that the death rate among children diagnosed with severe falciparum malaria was almost one-fourth lower when they received the drug artesunate rather than the standard treatment of quinine, according to research which was presented at the American Society for Tropical Medicine and Hygiene (ASTMH) over the weekend and published Monday in the Lancet, HealthDay News/U.S. News and World Report writes.

10 Nov 2010

New malaria drug can save millions of lives: Study

A landmark trial showed that the replacement of the standard malaria drug Quinine with the newer drug Artesunate for children with severe malaria could save 100,000 lives a year. The World Health Organisation (WHO) recommended that artesunate derived from a Chinese plant called sweet wormwood, replace the four-century-old remedy of quinine for treating severe malaria in adults in 2006. Similar recommendations were not made for children with further trial results pending.

8 Nov 2010

Advanced Life Sciences enters CRADA for Restanza with Walter Reed Army Institute of Research

Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced that it has entered into a Cooperative Research and Development Agreement ("CRADA") with The Walter Reed Army Institute of Research.

2 Nov 2010

FDA approves NUEDEXTA capsules for pseudobulbar affect

AVANIR Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved NUEDEXTA (dextromethorphan hydrobromide and quinidine sulfate) capsules, as the first treatment for pseudobulbar affect.

30 Oct 2010

Taste receptors in lungs can revolutionize treatment option for asthma

Taste receptors in the lungs. Researchers at the University of Maryland School of Medicine in Baltimore have discovered that bitter taste receptors are not just located in the mouth but also in human lungs. What they learned about the role of the receptors could revolutionize the treatment of asthma and other obstructive lung diseases.

25 Oct 2010

Researchers discover novel compound to combat drug resistant malaria

Novartis announced today that scientists at the Novartis Institute for Tropical Diseases (NITD), in collaboration with researchers from the Genomics Institute of the Novartis Research Foundation (GNF), the Swiss Tropical and Public Health Institute and The Scripps Research Institute have discovered a novel compound that shows promise as a next generation treatment for drug resistant malaria.

3 Sep 2010

People insensitive to quinine's bitter taste may have varied absorption, metabolization capabilities: Study

Some people find quinine to be bitter while others can drink it like water. Now, scientists from the Monell Center and collaborators report that individual differences in how people experience quinine's bitterness are related to underlying differences in their genes.The findings, published online in the journal Human Molecular Genetics, demonstrate that genetic variation in regions of DNA that encode bitter taste receptors predicts a person's perception of bitterness from quinine.

3 Aug 2010

Qualaquin for treatment of night time leg cramps leads to serious side effects, FDA warns

The U.S. Food and Drug Administration today warned that the unapproved use of the malaria drug Qualaquin (quinine sulfate) to treat night time leg cramps has resulted in serious side effects and prompted the manufacturer to develop a risk management plan aimed at educating health care professionals and patients about the potential risks.

9 Jul 2010

JANUMET results in greater blood sugar reductions in patients with type 2 diabetes compared to pioglitazone

New data were presented at the American Diabetes Association 70th Annual Scientific Sessions from a study comparing JANUMET (sitagliptin/metformin) to pioglitazone. In this study, JANUMET resulted in significantly greater blood sugar reductions in patients with type 2 diabetes compared with pioglitazone.

28 Jun 2010

Restanza shows greater efficacy against species of Plasmodium that cause malaria

Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced positive results from in vitro and in vivo studies assessing the efficacy of Restanza (cethromycin), its novel oral antibiotic, against the species of Plasmodium that cause malaria.

27 May 2010

Abbott's new FreeStyle Lite blood glucose test strips receive FDA clearance

Abbott today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration for its new FreeStyle Lite blood glucose test strips. The new FreeStyle Lite test strips minimize interference during blood glucose testing and are designed to offer a better testing experience.

24 May 2010

New research project to make anti-malarial drugs more affordable in Third World countries

Dr Geoff Brown, from the University of Reading's Department of Chemistry, is beginning a £400,000 project that could prove vital for the developing world in its ongoing fight against malaria. His research aims to make anti-malarial drugs more affordable in Third World countries where more than 1.5 million people die of the disease every year.

24 Apr 2010

700 scientists to present new information on smell and taste at AChemS 32nd annual meeting

The Association for Chemoreception Sciences (AChemS), a US-based scientific organization, is holding its 32nd annual meeting. About 700 scientists are gathering to present new information on the role of smell and taste in disease, nutrition and social interactions in humans as well as animals. Smell and taste play essential roles in our daily lives. These chemical senses serve as important warning systems, alerting us to the presence of potentially harmful situations or substances, including gas leaks, smoke, and spoiled food.

17 Apr 2010

AAN guideline evaluates drugs’ safety and efficacy for treatment of muscle cramps

A new guideline from the American Academy of Neurology recommends that the drug quinine, although effective, should be avoided for treatment of routine muscle cramps due to uncommon but serious side effects.

23 Feb 2010

Researchers discover chemical compound to combat malaria and bacterial diseases

Researchers report that they have discovered - and now know how to exploit - an unusual chemical reaction mechanism that allows malaria parasites and many disease-causing bacteria to survive. The research team, from the University of Illinois, also has developed the first potent inhibitor of this chemical reaction.

16 Feb 2010

Research suggests ancient Egyptians may have used lead-based cosmetics to prevent eye infections

There's more to the eye makeup that gave Queen Nefertiti and other ancient Egyptian royals those stupendous gazes and legendary beauty than meets the eye. Scientists in France are reporting that the alluring eye makeup also may have been used to help prevent or treat eye disease by doubling as an infection-fighter.

12 Jan 2010

New technological system to help improve availability of anti-malarial drugs in Tanzania

A new solution developed by IBM ( IBM), Novartis and Vodafone with the Roll Back Malaria Partnership, is helping to save lives using everyday technology to improve the availability of anti-malarial drugs in remote areas of Tanzania.

14 Dec 2009

Safety profiles of JANUVIA and JANUMET drugs established through clinical development program

Merck has thoroughly reviewed the safety data for sitagliptin, and sitagliptin was not associated with an increase in the incidence of pancreatitis in preclinical studies or in clinical trials of up to two years in duration with more than 6,000 patients.

28 Sep 2009

European CHMP recommends Merck's JANUVIA and JANUMET as add-on to insulin

Merck & Co., Inc., which operates in many countries as Merck Sharp & Dohme (MSD), has received a positive opinion from the European Medicines Agency’s (EMEA) Committee for Medicinal Products for Human Use (CHMP) for JANUVIA® tablets and JANUMET® tablets recommending their use as add-on to insulin for the treatment of type 2 diabetes.

26 Sep 2009